Related Experiment Video
Updated: May 3, 2026
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Randomized Phase II trial of nintedanib, afatinib and sequential combination in castration-resistant prostate cancer
L Rhoda Molife1, Aurelius Omlin, Rob J Jones
1Drug Development Unit, Divisions of Cancer Therapeutics & Clinical Sciences, Institute of Cancer Research/Royal Marsden Hospital, Downs Road, Sutton, Surrey, UK.
Aims:
The aim of this article was to evaluate afatinib (BIBW 2992), an ErbB family blocker, and nintedanib (BIBF 1120), a triple angiokinase inhibitor, in castration-resistant prostate cancer patients.
Patients & Methods:
Patients were randomized to receive nintedanib (250 mg twice daily), afatinib (40 mg once daily [q.d.]), or alternating sequential 7-day nintedanib (250 mg twice daily) and afatinib (70 mg q.d. [Combi70]), which was reduced to 40 mg q.d. (Combi40) due to adverse events. The primary end point was progression-free rate at 12 weeks.
Results:
Of the 85 patients treated 46, 20, 16 and three received nintedanib, afatinib, Combi40 and Combi70, respectively. At 12 weeks, the progression-free rate was 26% (seven out of 27 patients) for nintedanib, and 0% for afatinib and Combi40 groups. Two patients had a ≥50% decline in PSA (nintedanib and the Combi40 groups). The most common drug-related adverse events were diarrhea, nausea, vomiting and lethargy.
Conclusion:
Nintedanib and/or afatinib demonstrated limited anti-tumor activity in unselected advanced castration-resistant prostate cancer patients.
Insights
Nintedanib showed limited efficacy in castration-resistant prostate cancer patients, with a 26% progression-free rate at 12 weeks. Afatinib and combination therapies demonstrated minimal anti-tumor activity.
Area of Science:
- Oncology
- Pharmacology
Background:
- Castration-resistant prostate cancer (CRPC) remains a significant clinical challenge.
- Targeted therapies are being investigated to improve outcomes in advanced CRPC.
Purpose of the Study:
- To evaluate the efficacy and safety of afatinib, a triple angiokinase inhibitor, and nintedanib, an ErbB family blocker, in patients with advanced castration-resistant prostate cancer.
Main Methods:
- A randomized trial involving 85 patients with advanced CRPC.
- Patients received nintedanib, afatinib, or a combination of both drugs (Combi70, reduced to Combi40 due to adverse events).
- The primary endpoint was the progression-free rate at 12 weeks.
Main Results:
- Nintedanib monotherapy achieved a 26% progression-free rate at 12 weeks; afatinib and Combi40 groups had 0% progression-free rate.
- Two patients experienced a ≥50% decline in prostate-specific antigen (PSA).
- Common adverse events included diarrhea, nausea, vomiting, and lethargy.
Conclusions:
- Nintedanib and afatinib demonstrated limited anti-tumor activity in unselected patients with advanced castration-resistant prostate cancer.
- Further research may be needed to identify patient subgroups who could benefit from these agents.
More Related Videos
08:38Renal Capsule Xenografting and Subcutaneous Pellet Implantation for the Evaluation of Prostate Carcinogenesis and Benign Prostatic Hyperplasia
Published on: August 28, 2013
12:13Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
Published on: November 19, 2019
